Billionaire Warren Buffett's Berkshire Hathaway gained $60 million on Biogen shares after the drugmaker's stock surged to a record high on Monday. This comes after the US approved Biogen's Aduhelm drug, the first Alzheimer's treatment to get the green light in nearly two decades. Berkshire's stake in the drugmaker has jumped in value by $75 million in 18 months.